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COVID-19 is a contagious disease emerged by severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), it was primarily recognized in 2019 in Wuhan, China 
and has led to the 2019–20 coronavirus pandemic declared 
by world health organization(WHO) and a Public Health 
Emergency of International Concern (PHEIC).[1, 2] Coronavi-
ruses (CoVs) are a big family of viruses[3] that results in a va-
riety of illness ranging from common cold to more serious 
diseases i.e. Middle East Respiratory Syndrome [MERS] and 
Severe Acute Respiratory Syndrome [SARS]. It has many 
types which damage respiratory system and gastrointesti-
nal system.[3] Certain well-known CoVs are present in ani-
Several drugs are presently undergoing clinical studies to investigate their efficacy and safety in the handling of 2019 
coronavirus disease (COVID-19). Despite of the fact, certain encouraging results have been obtained thus far, however, 
these treatments have resulted in controversy as these are not based on data generated from direct conventional clini-
cal trials. As the legal requirement for approval of drug is "substantial" evidence of effectiveness demonstrated through 
controlled clinical trials and requires a large portion of time. A number of clinical trials are currently in progress to evalu-
ate possible therapies, but the worldwide reaction to the COVID-19 outbreak has been mostly restricted to monitoring/
suppression. In the meantime, scientists are struggling to discover antivirals specific to the virus either by screening/
testing available broad-spectrum antiviral drugs or redevelopment of newer particular drugs based on individual coro-
navirus (CoV) genome. Upto date, the hypothetical and experimental treatment approaches against COVID-19 that are 
tested or being testing are the use of antimalarial and antibiotics, antivirals, anti-parasitic, immunomodulators, antico-
agulant treatment, antihypertensive, chinese traditional medicines and others (high temperature and high humidity) 
as well as vaccines development. This review summarized all the literature-based treatment approaches in various ways 
that are implementing for the management or treatment of COVID-19.
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mals that have not so far affected humans. A novel CoV-2 
(nCoV-2) is a newer strain that has not been formerly recog-
nized in humans. The WHO China Country Office was noti-
fied of a cluster of pneumonia cases of unidentified origin 
in Wuhan City on 31 December 2019. A nCoV-2 was isolated 
and determined as the causative virus by Chinese authori-
ties on 7 January.[4, 5] Later, the disease was officially named 
as COVID-19 on 11 February, 2020.[6, 7] Generally, COVID-19 
patients with pneumonia have a fever, and the tempera-
ture above 38 degrees with symptoms such as dry cough, 
fatigue, dyspnea, difficulty breathing, and frost-glass-like 
symptoms in the lungs.[8-10] The disease is highly transmit-
table[10, 11] and ever since it has spread worldwide quickly[1] 
and become a world-wide public health challenge.[6] As of 
May 05, 2020 more than 3, 517, 345 cases have been re-
ported, and more than 243, 401 have lost their lives within 
215 countries, areas or territories.[12]
The COVID-19 is transmitted through inhalational route 
or due to contact with large infected droplets eliminated 
while coughing/sneezing by symptomatic as well as as-
ymptomatic patients.[13, 14] It can be diagnosed from various 
respiratory samples (such as nasopharyngeal swab, throat 
swab, endotracheal aspirates, sputum and bronchoalveo-
lar lavage) through particular molecular tests.[13] In several 
severe cases, the virus can also be identified in the stool 
and blood. Comparatively, the nasal cavity has more viral 
loads than the throat with same viral burden within symp-
tomatic and asymptomatic people.[15] The patients can be 
contagious until the symptoms remain and even after re-
covery.[13] The mechanism by which the virus gets entry to 
the respiratory mucosa has recognized to be the angioten-
sin receptor (ACE)-2.[16] A study demonstrated that in the 
pathogenesis of COVID-19, a cytokine storm occurred[6] 
such as tumour necrosis factor (TNF)-α, interleukins-(IL)-2, 
(IL)-6,(IL)-7, (IL)-10 etc. resulting in the severity and progres-
sion of disease.[6, 7, 17] In brief, the inspiration of droplets con-
taining SARS-CoV-2 infects ACE-2 expressing target cells 
like alveolar (type)-2 cells or other unidentified target cells. 
Intensified replication of virus occurs due to inhibition of 
anti-viral IFN (interferon) responses by the virus. The enrol-
ment of neutrophils and monocytes/macrophages results 
in the induction of pro-inflammatory cytokines that results 
in immunopathology of lungs and prognosis of disease.
[18] Additionally, the presence of inflammatory mediators 
induces febrile responses by binding with its respective re-
ceptor present in the hypothalamus, results in pyrexia.[19]
Right now, due to lack of vaccine or specific antiviral treat-
ment for human and animal CoVs, urgent identification of 
drug treatments for the response to the COVID-19 outbreak 
is the utmost requirement.[20] However, until now some of 
general methods have been practiced or still being prac-
ticing to discover the potential treatment for COVID-19. 
These methods include evaluation of available broad-spec-
trum antiviral drugs by means of standard assays, which 
have been consumed for treating other viral infections,[21] 
screening of a chemical library comprising various current 
compounds/databases, containing information related 
transcription characteristics in distinct cell lines,[22] and re-
inforcement of newer specific drugs based on the genome 
and biophysical chemistry of respective coronaviruses.[23] 
Upto date, several treatment options (Table 1) have been 
hypothesized and various drugs have been tested such 
as some existing antimalarial, antivirals, antibiotics, anti-
inflammatory, immunomodulators and some traditional 
treatment against COVID-19. Some of them have been 
achieved promising results so far.[24] However, the efficacy 
and safety of these drugs for COVID-19 still require to be 
further proved by clinical experiments. This review article 
summarized upto date various hypothetical and experi-
mental treatment approaches against SARS-CoV-2 with 
evidence in details.
Methods
Search and Selection Strategy
A thorough literature search was conducted on recently 
published studies regarding treatment of COVID-19 which 
have published since the outbreak. Related articles, some 
editorial, letter to editor and correspondence which de-
scribed about the current treatment process and drugs op-
tions for COVID-19 infection were extracted from scientific 
databases including Google Scholar, Medline, PubMed, and 
Science Direct with keywords “Covid-19 treatment”, “Treat-
ment for Covid-19”, “Covid-19 AND Treatment”, “Current 
drug treatments for Covid-19”, “Antimalarial AND Covid-19”, 
“Antivirals AND Covid-19”, “NSAIDs AND Covid-19”, “Chinese 
traditional medicine AND Covid-19”, “Immunosuppressant 
AND Covid-19”, “Anticancer AND Covid-19”, Vaccine AND 
Covid-19”.EndNote X 7.2.1 software was used for referenc-
ing and to exclude duplicates from searched data.
Treatment Approaches Against COVID-19
Antimalarial
Chloroquine
Chloroquine is a medication utilized to inhibit and treat 
malaria and is effective as an anti-inflammatory drug for 
treating lupus erythematosus and rheumatoid arthritis.[25] 
It’s in vitro antiviral activity has been recognized since the 
end of 1960's and the growth of many various viruses can 
be repressed in cell culture by chloroquine, including the 
SARSCoV.[26] Recently, precise pre-clinical proof and expert 
ideas recommend possible use against SARS-CoV-2 and a 
search in trial registries demonstrates that 23 clinical tri-
als were conducted just in China until March 2020.[27] It has 
been progressively learnt that the anti-inflammatory and 
anti-viral actions of chloroquine may share in the treatment 
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Table 1. Different treatment approaches and their effectiveness against COVID-19
Drug Name Indications Effectiveness against COVID-19
Chloroquine −Anti-malarial −Increases endosomal pH and interferes with the glycosylation of   
  −Anti-inflammatory cellular receptor of SARS-CoV
   −Effective in ( EC50) of 1.13 & 5.47 μM in vitro
   −Suggested dose: 500 mg twice daily for 10 days
Hydroxychloroquine (HCQ) −Analog of chloroquine −Similar to chloroquine, HCQ alters the pH and confers antiviral effects
  −Anti-malarial −More potent agent than chloroquine in inhibiting SARS-CoV-2 in vitro
  −Anti-rheumatic −Effective in EC50 of 0.72 μM in vitro
   −A loading dose of 400 mg twice daily give orally, followed by a   
   maintenance dose of 200 mg given twice daily for 4 day suggested for  
   COVID-19 
Hydroxychloroquine (HCQ) + −Anti-bacterial activity −After 6 days of treatment with HCQ (600 mg/day) + AZM (500 mg for  
   1 day
Azithromycin (AZM) −Immunomodulatory effects followed by 250 mg/day upto 4 days) showed 100 % nasopharyngeal  
   clearance of virus in human 
Remdesivir −Broad spectrum antiviral −A highly potent WHO recommended drug with confirmed inhibiting  
  −Adenosine nucleotide analogues activity against SARS-coV-2 by blocking the viral RNA polymerases
   −A 10 days treatment course with 200 mg loading dose on day 1 and  
   100 mg daily I/V up to remaining 9 days
Lopinavir/ritonavir (LPV/r) −Antiretrovirals −The antiretrovirals in combination has the capacity to combat CoV-19 by
  −Protease inhibitors hitting the viral protease and stopping its replication
  −Approved for HIV-1 treatment −Mostly efficient in mild corona virus cases with oral dosage of 200/50 mg  
   2×BID for 7 days
Oseltamivir −Antiviral −No evidence in SARS and MERS
  −Neuraminidase inhibitor −Very few mild COVID-19 reported cases got cured with Oseltamivir  
  −Anti-influenza agent along with antibiotics and supportive care 
   −Suggested dosage in mild cases include 4-6mg/kg with 800mg HCQ  
   each day orally
Duranavir −Antiviral −No significant results against COVID-19
  −HIV Protease inhibitors −The drug cannot block properly the viral protease, also require very 
   −Anti-HIV medication high dosage confirmed from several trials
   −Used under trials at recommended oral dose of 800mg every 8 hours in  
   combination with Ritonavir (200mg) and Oseltamivir (300mg) per day
Favipiravir −Broad-spectrum antiviral −Showed some potency against CoV infection with lesser adverse   
  −RNA polymerase inhibitors effects than against influenza lopinavir/ritonavir
    −Considered for experimental tests with loading dose of 2400 mg on  
   day 1 and maintenance dose of 1200mg every 8 hours in combination with
   Lopinavir (800mg), Ritonavir (200mg) per day
Umifenovir/Arbidol −Antiviral −Effective against viral entry to host cell
  −Membrane fusion inhibitor −Can effectively inhibit COVID-19 infection at a concentration of 10-30  
  −influenza treatment drug µM in vitro
    −A seven-day treatment course of 200mg dose three times a day is  
   suggested
Ribavirin  −Antiviral −Showed positive outcomes during the previous outbreaks of MERS  
  −Anti-RSV and SARS
    −Currently conducted clinical trials proved the potential efficacy of  
   ribavirin with recommended dose of 500mg IV BID or TID
  −Anti-HCV −However, some experts are recommending to be used in   
   combination with other antivirals (IFN-α or LPV/r) for better results
Ivermectin −Antiparasitic −In vitro the solo treatment is strong enough to effect nearly 5000-fold  
   drop in virus concentration at 48h in cell culture
  −Nuclear transport inhibitor −Therefore, full attention with priority basis clinical trials to be needed  
   to get evidence-based results about this emerging drug
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Table 1. CONT.
Drug Name Indications Effectiveness against COVID-19 
NSAIDs −Anti-inflammatory −It’s use has been controversial in COVID-19
   −Link with respiratory and CVS adverse events
   −Among them, Indomethacin has reported a strong antiviral activity  
   in-vivo and in human SARS-CoV at a dose concentration of 1 mg/kg
Corticosteroids −Inflammatory modulators −Various studies recommended the use of corticosteroids as preferred  
(Glucocorticoids)  over NSAIDS for COVID-19 treatment
   −However, WHO has not recommended its routine administrations in  
   patients with COVID-19
Combining anti-viral and −Janus kinase inhibitor −Baricitinib, Fedratinib and Ruxolitinib were expected to be beneficial  
   in COVID-19 anti-inflammatory treatments
   −It was also expected that combinations of Baricitinib with direct-  
   acting antivirals i.e. ((LPV/r, Remdesivir) might diminish viral replication
Tocilizumab −Immunosuppressant −An effective drug in severe individuals with COVID-19
  −Anti-IL-6 receptor −Reduced fever and oxygen requirement in COVID-19
  −Anti-rheumatoid arthritis −Phase II clinical trial study launched on March 20 2020 holding in Italy
   in COVID-19 patients group received a dose of 8 mg/kg (up to a   
   maximum of 800mg per dose), with an interval of 12 hours by   
   intravenous infusion
BCG Vaccine −Attenuated antitubercular vaccine −Stimulate immune system to produce specific immunoglobulin   
   against virus
   −Postulated that until a specific vaccine is developed, SARS-CoV-2  
   vulnerable populations could be immunized with BCG vaccines to
   attain heterologous nonspecific protection from the new coronavirus
Monoclonal antibody therapy −Passive (IgG) immunoglobulin-G  −There are many reported monoclonal antibodies directing the RBD  
  −Immunotherapy region of S protein of SARS-CoV and MERS CoV which showed
   promising results in vitro and in vivo that could be theoretically   
   effective against COVID19
Plasma therapy −I.V immunoglobulin treatment −Neutralization of COVID19 particles through stimulation of
  −Passive (IgG) immunoglobulin-G antibody-dependent cellular cytotoxicity or phagocytosis
   −Suggested dose is 1 unit (500 ml) convalescent plasma introduce  
   directly after the onset of symptoms
Interferon (IFN) alpha 2b −Immunomodulators −Interferon is known to have cured more than 1,500 patients with  
  −Antiviral coronavirus and is among the drugs of choice for the WHO
   −The suggested method for administration of IFN-α is vapor inhalation
   at a dose of 5 million U (and 2 mL of sterile water for injection) for   
   adults, 2 times/day.
Anti-cytokines −IL-6 & TNF- α inhibitors  −Anti-cytokines can manage CoV-19-induced (CRS) Cytokine release  
  −Anti-inflammatory syndrome which is a deadly multiple organ dysfunction in the body of  
  −Immunomodulators CoV-19 patients
   −Some of the anti-interleukin drugs in treating COVID-19 CRS are   
   under experimental testing and trials
Anticoagulant treatment −Coagulation disorders −The use of anticoagulant for severe coronavirus disease 2019   
   (COVID-19) treatment has been recommended in patients   
   with coagulopathy
   −LMWH is the best and used as prophylactic dose due to its anti-  
   inflammatory effect, its ability to prevent DIC and SIC
Antihypertensive drugs −Lowering Blood Pressure −Regardless of the absence of proof, there have been thoughts for  
   both the continuation and termination of ACE-Is, AR-Bs, or both
   throughout the treatment for COVID-19 in patients with hypertension
Traditional chinese −Traditional uses −Previous clinical evidence on CM prevention for similar public health  
medicines (CM)  emergencies such as SARS and H1N1 influenza has been reported
   −Recently, a highly suspected case of novel coronavirus pneumonia 
   were recovered with the use of CM
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of patients with novel COVID-19 and these actions have di-
rected to several trials instantly in the face of international 
health emergency.[28] Chloroquine elevates endosomal pH 
and interferes with the glycosylation of cells surface recep-
tor of SARS-CoV and thus it has the potency to prevent viral 
infection.[29]
The early in vitro studies found that chloroquine could stop 
COVID-19 infection by low micro molar (μM) concentra-
tion, with a half-maximal effectual concentration (EC50) 
of 1.13 μM and a half-cytotoxic concentration (CC50) more 
than 100 μM.[25, 29] Similarly, in the study by Yao et al.,[30] in-
vitro chloroquine was shown to have an inhibitory effect 
on SARS-CoV-2 with an EC50 value of 5.47μM. There were 
some consequent clinical trials have been quickly estab-
lished in China to examine the effectiveness and safety of 
chloroquine or hydroxychloroquine in treating COVID-19 
related pneumonia in >10 hospitals in Wuhan, Jingzhou, 
Guangzhou, Beijing, Shanghai, Chongqing, and Ningbo.
[31] A Chinese research including >100 individuals of CO-
VID-19 found chloroquine higher than to the control group 
in reducing symptom period, aggravation of pneumonia 
involving radiological enhancement and promoting virus-
negative seroconversion without any serious side effects.
[25] This was the first human experiment ever directed with 
chloroquine against COVID-19. This early outcome led Chi-
na to insert chloroquine in the treatment and prevention of 
COVID-19 pneumonia.[28] 
Furthermore, a meeting was conducted on February 15, 
2020; contributors including professionals from govern-
mental and regulatory authorities and organizers of clini-
cal experimental research came to a recommendation that 
chloroquine phosphate has potent action against COV-
ID-19.[25] The drug is recommended for addition in the next 
version of the Guidelines for the Diagnosis, Treatment, and 
Prevention of Pneumonia Caused by COVID-19 allotted by 
the National Health Commission of the People's Republic 
of China[25, 28] in which they stated that chloroquine should 
be administer in a dose of 500 mg of chloroquine two times 
daily for 10 days in mild to severe COVID-19 pneumonia.[28] 
Moreover, on 17 February 2020, the State Council of China 
briefed that chloroquine phosphate had demonstrated no-
ticeable efficacy and adequate safety in treating COVID-19 
related pneumonia in multicenter clinical trials organized 
in China.[31] Furthermore, the effectiveness of chloroquine 
has been reported by the “editorial written by French re-
searchers”,[32] “expert consensus published by a multicenter 
collaboration group of Guangdong Province”,[33] “Dutch 
Center of Disease control (CDC),[26] “Italian Society of Infec-
tious and Tropical disease”.[34] All these published literatures 
and clinical trials are summarized by Nitesh et al.[26, 34] and 
Cortegiani et al.[27] 
Hydroxychloroquine
Hydroxychloroquine (HCQ) is an analog of chloroquine 
and a less toxic aminoquinoline that has less fears about 
drug-drug interactions.[30, 35] Like chloroquine, HCQ chang-
es the pH and shows its antiviral effects. In addition, HCQ 
has a modifying effect on activated immune cells, decrease 
the expression of Toll-like receptors (TLRs) which leads to 
downregulation of TLR-mediated signal transduction, and 
lowering the interleukin-6 production.[36] In the former 
SARS outbreak, HCQ was described to have anti-SARS-CoV 
activity in vitro. This suggests that HCQ may be a poten-
tial pharmacological agent for the treatment of COVID-19 
infection.[30] Another reports determined that HCQ effec-
tively inhibited both the entrance, transportation and the 
post-entrance stages of SARS-CoV-2 as that of chloroquine 
and one study found HCQ to be a more potent agent than 
chloroquine in inhibiting SARS-CoV-2 in vitro.[30, 37]
Several clinical trials are currently investigating the use of 
HCQ to treat SARS-CoV-2 infection.[30] Up till February 23, 
2020, there were 7 clinical trial studies found in Chinese 
Clinical Trial Registry (http://www.chictr.org.cn) for using 
HCQ to cure COVID-19.[37] In one of those seven trials, a 
placebo controlled randomized research of two different 
doses of HCQ in 62 patients with radiological findings of 
pneumonia but without serious hypoxia, showed small 
enhancements in body fever and cough in the treatment 
group of higher dose.[38] Conversely, the endpoints de-
Table 1. CONT.
Drug Name Indications Effectiveness against COVID-19 
Temperature and Humidity −Environmental factor −Few studies conveyed that the COVID -19 was associated to the   
   climatological factors, which reduced with the temperature growing
COVID-1 (2019 coronavirus disease), SARS-CoV (severe acute respiratory syndrome coronavirus), EC50 (Half maximal effective concentration), WHO (World 
Health organization), SARS (Severe Acute Respiratory Syndrome), MERS (Middle East Respiratory Syndrome), HIV (Human Immunodeficiency Virus), HCV 
(Hepatitis C Virus), RSV (Respiratory Synctial Virus), BID (bis in die/two times), TID (ter in die/ Three times),  H1N1 (Hemagglutinin Type 1 and Neuraminidase 
Type 1 (influenza strain), ACE-Is (Angiotension converting Enzyme inhibitors), AR-Bs (Angiotension Receptor Blockers), LMWH (Low Molecular Weight 
Heparin), DIC (Disseminated intravascular coagulation), SIC (Sepsis-Induced Coagulopathy), RBD (Receptor-Binding Domain).
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scribed in the published protocol varied from those speci-
fied, the outcome in the low dose group were not defined, 
and the trial looks to have been discontinued before the 
due time.[39] A previous non-randomized research of HCQ, 
published in preprint, apparently supported efficiency 
in 20 individuals, but the trial plan was weak and the re-
sults uncertain: six individuals gave up the treatment arm 
(2 due to an admission in intensive care unit (ICU) and 1 
because he died); the degree of efficacy was viral load, not 
a clinical endpoint; and evaluations were made on day 6 
after initiating the treatment.[40] Supporters, including US 
President Donald Trump, claimed that HCQ is broadly used 
and harmless. It is now approved by the US Food and Drug 
Administration (FDA) for use[41] and also supported by the 
Indian Council for Medical Research.[28] However, no drug 
is certain to be harmless or free of side effects, and wide 
use of HCQ will expose some users to rare adverse reaction 
events.[42]
In a study by Yao et al.,[30] theanti-SARS-CoV-2 activity of 
HCQ was investigated in vitro by means of SARS-CoV-2 in-
fected Vero cells. HCQ (EC50=0.72 μM) was showed to be 
more potent than chloroquine (EC50=5.47 μM) in vitro. This 
was demonstrated by the EC50 values for HCQ always be-
ing smaller than the EC50 values for chloroquine, indicat-
ing that HCQ has a more potent antiviral activity.[30] On the 
basis of HCQ’s superior antiviral and prophylactic activity, 
as well as its more tolerable safety profile in comparison to 
chloroquine, it was believed that HCQ may be a promising 
drug for the treatment of SARS-CoV-2 infection.[30, 43] De-
pending on PBPK (Physiologically-Based Pharmaco Kinetic) 
models results, a loading dose of 400 mg two times daily 
of HCQ sulfate administered orally, followed by a main-
tenance dose of 200 mg given twice daily for 4 days was 
recommended for SARS-CoV-2 infection.[30] Moreover, a 
Central Clinical Task Force from Korea who have treated 27 
cases of SARS-CoV-2 infection recommend using Hydroxy-
chloroquine 400 mg orally per day for 7-10 days, in moder-
ate to severe case of COVID-19.[28]
Antimalarial and Antibiotic
Hydroxychloroquine and Azithromycin
Some of the old drugs such as Macrolides were anticipat-
ed for their effectiveness against COVID-19, based on the 
structure based selection of drugs for specific identification 
of SAR-CoV-2 protease inhibitors. Macrolides (MAC) such 
as erythromycin, clarithromycin, and azithromycin (AZM) 
not only have anti-bacterial activity but also have immu-
nomodulatory effects, including anti-inflammatory effects. 
Latterly, macrolides have gained robust attention because 
of their anti-viral effects. Recent studies reported the effec-
tiveness of AZM administration in combination with HCQ.
[40] Moreover, it is noteworthy to mention the promising ef-
fects of macrolides either administered alone or in combi-
nation with other drugs has paved the way to devise some 
international strategies to cope the rapid emergence of 
this viral infection.[44]
In March 2020, a human study (n=36) as an open label non-
randomized trial was conducted in Méditerranée Infection 
University Hospital Institute, Marseill, France by Gautret et 
al.[40] Twenty of thirty-six received active treatment with a 
total 600 mg/day of HCQ and their nasopharyngeal swab 
samples were subjected to test for viral load. Based on their 
clinical condition, AZM was added to their treatment regi-
men, about six of these 20 were administered AZM (500 
mg for 1 day administration followed by 250 mg/day upto 
4 days administration) to prevent bacterial superinfection. 
Sixteen control patients did not receive these active treat-
ments. Their samples were evaluated on Day-6 for the vi-
ral presence or absence, the end point was considered as 
Day-6 post.[40, 45] The findings of this research explained that 
HCQ either alone or in combination with AZM exhibited 
significant effects in abstaining nasopharyngeal viral loads 
(samples evaluated by PCR), within 3-6 days in COVID-19 
subjects as compared to controls.[40] At day 6, out of the 20 
treated patients, 100% of HCQ/AZM, 57.1% HCQ only and 
12.5% of the control group showed nasopharyngeal clear-
ance of virus.[45] These preliminary findings suggested that 
the combination treatment of AZM and HCQ could have a 
synergistic effect. 
However, these findings needed to be further explored 
for the significance of a combination treatment as more 
effective and safe because of AZM association with QR in-
terval prolongation and arrhythmia, most importantly in 
outbreak of severe cases. Future studies emphasizing this 
combination treatment are required, as this combination 
might be a potential candidate as an antiviral agent against 
SARS-CoV-2 as well as can be effective in preventing sev-
eral bacterial super-infection.[40] In addition, every adult 




Remdesivir, a prodrug of a nucleotide equivalent that pre-
vents the action of viral RNA polymerases. During the past 
outbreaks occurred due to members of few other virus 
families containing Filoviruses (e.g., Ebola) and MERS-CoV 
(e.g., SARS-CoV) and the antiviral remdesivir is considered 
to possess broad-spectrum activity against these viruses. 
It has also been reported from several studies that the 
271EJMO
drug holds therapeutic efficacy and prophylactic activity 
in many nonclinical models of the above coronaviruses.[29, 
47, 48] Recently, when there is a race to find a potent drug 
candidate, remdesivir was also tested in vitro and results 
has presented that it has prominent activity against SARS-
CoV-2 and chosen as a strong candidate. In the late January 
of this year a chemist Wenshe Ray Liu along with his group 
members of Texas A&M University were the foremost to 
recognize remdesivir as a practical medicine to combat 
COVID-19.[49]
The first case of COVID-19 reported in the US was a young 
man in Snohomish County in Washington. He was admin-
istered with antiviral remdesivir when his condition be-
came severe; and surprisingly the doctors found him well 
the next day. A Californian patient whose doctors thought 
to not survive the disease, he was given remdesivir and 
recovered as well.[50] A study reported a total of 53 infec-
tion cases of COVID-19 that were hospitalized in several 
affected countries, were treated with remdesivir and 68% 
improvement was observed in clinical conditions of 36 pa-
tients. These patients received the drug between January 
25 and March 7,2020, in hospitals around the world: 22 in 
Europe, 22 in the USA and 9 in Japan.[51] A news released by 
NIH on 25th February of this year has reported that random-
ized, controlled clinical trial, to assess the security, safety 
and effectiveness of tentative remdesivir antiviral in adults 
being hospitalized with COVID-19, has started in Omaha at 
the University of Nebraska Medical Center (UNMC).[52]
A report published in the journal of NATURE biotechnology 
stated that the broad-spectrum antiviral “remdesivir has 
quite high potency against all different CoVs and therefore 
it is selected as one of the prime and suitable drug candi-
dates to start being tested”.[53] WHO in the mid of March had 
launched an international level mega trial of the 4 most 
auspicious treatments against CoV including remdesivir on 
top of list with higher potency and efficacy. According to 
their study the nCoV-2 is giving this compound a second 
chance to shine. The original pioneer of remdesivir “Gilead 
Sciences” developed the drug to combat Ebola and related 
viruses by blocking the RNA-dependent RNA polymerase 
of pathogens. A professor named Shibo Jiang from Fudan 
University in China, who is known for his expertise on CoV 
therapeutics, stated that “remdesivir has the best potential 
to be used in clinics” for treatment of COVID-19. A 10 day 
treatment course with 200 mg loading dose on day 1 and 
100 mg daily I/V up to remaining nine days has suggested.
[54] A virtual meeting held on 2nd April,2020 among mem-
bers of EMA’s (Human Medicines Committee) provided rec-
ommendations on concerned usage of remdesivir as effi-
cient antiviral for COVID-19 medication.[55]
Lopinavir/ritonavir (LPV/r)
Lopinavir is an antiretroviral protease inhibitor adminis-
tered in combination with other antiretrovirals in the treat-
ment of HIV (Human Immunodeficiency Virus)-1 infection. 
Ritonavir is an inhibitor of the enzymes responsible for 
lopinavir metabolism, and its co-administration "boosts" 
lopinavir exposure and antiviral activity.[31] Lopinavir is a 
peptidomimetic molecule and it contains a hydroxy-ethyl-
ene scaffold that imitate the peptide linkage which is char-
acteristically targeted by the HIV-1 protease enzyme and 
alongside itself cannot be slinter, thus stopping the activ-
ity of the HIV-1 protease.[56] Similarly, in COVID-19 the virus 
needs viral protease to have its replication, so the antiviral 
medication of lopinavir might be operational by binding 
to the protease of CoV to hinder virus-related replication. 
Some of the earlier studies[57, 58] have been displayed that 
lopinavir could prevent MERS-CoV and SARS-CoV replica-
tion. 
Recently, it is reported from a case study conducted in 
Guangdong Center for Disease Prevention and Control, 
China that a patient with COVID-19 pneumonia was treat-
ed with LPV/r (200/50 mg twice daily two tablets) antivi-
ral therapy along with other medical necessities. After the 
8 days of treatment, the SARS-CoV-2 nucleic acid test re-
sults were negative from his throat and swab samples two 
times with notable improvement in cough and computed 
tomographic chest images. The patient has recovered and 
declared safe and healthy by doctors and was discharged 
from the hospital.[59] Moreover, another study reported 
that lopinavir alone or in combination with ritonavir have 
anti-CoV activity in vitro 20. From the Moscow City Health 
Department's website, a recommendation published on 
25th March, 2020 stated that the experts recommended the 
(LPV/r) medication successful against mild CoV cases.[18] A 
Molecular Docking study conducted by Dayer M R et al. in 
Iran also found that lopinavir is a potent drug against CoV 
infection.[20] The suggested dosage of lopinavir/ritonavir is 
400 mg/100 mg for adults, BID.
Oseltamivir 
Oseltamivir an FDA approved drug for influenza A and B 
treatment works by blocking the viral neuraminidase and 
subsequently prevent the release of viral particles from 
host cells.[60] In china, clinical trials were established to test 
oseltamivir alone or with combination of chloroquine and 
favipiravir as a treatment option for COVID-19.[16, 61] A study 
conducted by School of Public Health in Hong Kong Uni-
versity stated that the antiviral oseltamivir does not show 
any notable effects on nCoV-2.[62] Another study docu-
mented two retrospective case series about oseltamivir ef-
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fectiveness against COVID-19 with contradictory results. In 
one case series, it is reported that out of 138 patients 124 
received oseltamivir with adjusted dose according to the 
severity of disease but noted no effective outcomes.[63] In 
the 2nd Case series, Ding et al. reported the clinical char-
acteristics and care for 5 patients being co-infected with 
both the influenza virus and COVID-19. All of the patients 
have been treated with antiviral treatment (together with 
oseltamivir), antibiotics and supportive care. All patients 
obtained complete recovery and were discharged from 
hospital.[64] At present, 3 clinical trials of oseltamivir in com-
bination with other medications are being ongoing for the 
treatment of COVID-19 with estimated completion in next 
few months.[46]
Darunavir
Another HIV protease inhibitor, darunavir and the boosting 
agent cobicistat, is also under evaluation. A study based 
on circumstantial findings, stated this protease inhibitor 
has formerly shown great efficacy against SARS associated 
CoV, though it has not been verified safe and potent for the 
treatment of COVID-19 and thus additional conformation-
al studies need to investigate. In China, Shanghai Public 
Health Clinical Center (SPHCC) have worked in collabora-
tion with Zhongnan Hospital to find out some potentially 
efficient drugs against COVID-19 and to achieve this up to 
30 effective and potent compounds including darunavir 
were examined. Later, SPHCC documented that the drug 
darunavir was not effective against COVID-19 during a 
randomized, controlled trial.[65] A report issued in detail by 
the darunavir/cobicistat manufacturer company “Janssen” 
about the activity of drug against COVID-19 that it does not 
bind well to the virus protease and the potency achieved 
in a lab-dish with much high dose than is attained in the 
body.[66]
Favipiravir
Favipiravir is an antiviral medicine which is significantly ef-
fective in COVID-19 treatment. The drug prevents viruses 
from replicating their genetic material. It is a pyrazine car-
boxamide derivative and initially discovered while exam-
ining for drugs to treat influenza. Report from doctors at 
China’s Wuhan University makes more modest claims. They 
controlled the study of 240 ordinary patients (those who 
were having mild pneumonia) around Hubei province. Half 
of them received umifenovir and the remaining favipira-
vir. They were under observation to examine which group 
recovered fast. The doctors observed that patient’s fevers 
and coughs disappeared more rapidly on favipiravir but 
similar number in each group ended up requiring oxygen 
or ventilator. On the basis of these findings, they concluded 
that favipiravir is the preferred of the two drugs. During the 
outbreak in China, a CoV-infected woman in her late 90’s af-
ter getting antiviral favipiravir therapy soon became better 
and was discharged from Leishenshan Hospital to observa-
tion facility. So far, this was the oldest critical patient that 
got cured.[67]
Moreover, favipiravir needs consideration because it was 
accepted for treating novel influenza on 15th Feb 2020 in 
China. The medicine is now experiencing more clinic trials 
in the COVID-19 treatment. This medicine is a fresh RNA-
dependent RNA polymerase (RdRp) type inhibitor. Along 
with its anti-influenza action, favipiravir is thought to be 
proficient of hindering the replication of many RNA viruses.
[24] Favipiravir being transformed into an active phosphori-
bosylated form (favipiravir-RTP) in cells renowned as a sub-
strate through viral RNA polymerase, hence constraining 
RNA polymerase action.[24] Consequently, favipiravir might 
possess potential antiviral action against SARS-CoV-2 that 
is an RNA virus. No significant adverse reactions were 
noted in the favipiravir treated set of patients, proposing 
that it had comparatively less unfavorable results than the 
(LPV/r) group.[24] Moreover, in Turkey intensive care (IC) pa-
tients with severe COVID-19 pneumonia had been started 
the use of favipiravir. Because of its effectiveness against 
clearance of virus, the health ministry approved it positive 
safe choice for early stage of pneumonia in hospitalized pa-
tients instead of IC unit (ICU) and this was thought to be the 
reason behind less admission ratio of ICU administration.[46]
Umifenovir [Fusion peptide (EK1)]
Umifenovir, antiviral medicine for influenza infection most-
ly consumed in Russia and China with the brand named ar-
bidol and its mechanism of action apply through blocking 
and inhibition of enveloped virus membrane fusion with 
host cell membrane, thus prevent virus from cell entry.[68]
Umifenovir exhibits modulatory effect on the immune sys-
tem along with its precise antiviral action against both in-
fluenza B and A viruses. This medicine triggers a humoral 
immune response, encourages interferon-production, and 
moreover excites the phagocytic function of macrophages.
[69] Arbidol was revealed to have a direct antiviral action in 
early viral reproduction in vitro for SARS-COV, the National 
Health Commission (NHC) of China for tentative therapy of 
COVID-19 have included arbidol in the newest version of 
the “Strategies for the Prevention, Diagnosis, and Treatment 
of Novel Coronavirus (COVID19)-induced Pneumonia”.[70] 
Arbidol should be administered orally at a dose of 200 mg 
for adults, 3 times/day. The period of treatment should not 
exceed 10 days. Recently, there was a study in China has 
stated that arbidol can effectively inhibit COVID-19 infec-
tion at a concentration of 10-30 µM in vitro.[24]
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One study reported that four patients with mild or se-
vere 2019-nCoV pneumonia have been cured or have sig-
nificant improvement in their respiratory symptoms after 
treatment with combined lopinavir/ritonavir, arbidol, and 
Shufeng Jiedu Capsule.[71] Moreover, another study in Chi-
na revealed that arbidol mix with LPV/r might be beneficial 
to retard the development of lung lesions and minimize 
the chances of respiratory and gastrointestinal transferring 
for reducing the viral load of COVID-19.[72] Furthermore, a 
randomized multicenter controlled clinical trial of arbidol 
in patients with 2019-nCoV (ChiCTR2000029573) has been 
initiated in China.[73] In February 2020, an expert Li Lanjuan, 
from the National Health Commission of China, suggested 
consuming arbidol in combination with darunavir as a pos-
sible treatment. Statement given by experts from China 
that preliminary tests have revealed darunavir and arbidol 
might prevent viral replication.[74]
Ribavirin
Ribavirin, an antiviral medicine typically given to cure Re-
spiratory Synctial Virus (RSV)-infection, some vial hemor-
rhagic fever and hepatitis C. To treat hepatitis C infection, it 
is given in combination with few other drugs like simepre-
vir, sofosbuvir, peginterferon-α2b/2a. Ribavirin being gua-
nosine equivalent consumed to halt viral mRNA capping 
and viral RNA synthesis, hence, it is known as nucleoside in-
hibitor. It is a prodrug which after being metabolized bear 
a resemblance to purine RNA nucleotides. In its later form, 
it interferes with viral RNA metabolism essential for its rep-
lication bringing alterations in RNA-dependent replication 
more specifically in RNA viruses. These kind of hyper mu-
tation could be fatal to RNA viruses. Similarly, in COVID-19 
which is also an RNA virus it can be administered to the 
patient and was given in the amount nearly 500 mg each 
time, twice to thrice per day along with IFN-α or (LPV/r).[75]
Antiparasitic Drugs
Ivermectin
Ivermectin prevents the growth of the SARS-CoV-2in vi-
tro. The solo treatment is strong enough to effect nearly 
5000-fold drop in virus concentration at 48h in cell culture. 
This drug has an advantage of being approved by FDA for 
parasitic infections treatment, hence, possess potential for 
repurposing. The drug is easily accessible thus permits fur-
ther analysis for potential benefits in humans. Ivermectin 
works to inhibit nuclear import of host and viral proteins. 
Essentially, it is considered to restrict many RNA virus infec-
tions.[76, 77]
Information suggesting that ivermectin nuclear transport 
inhibitory activity might be beneficial in conflict of SARS-
CoV-2. Vero/hSLAM cells infected with SARS-CoV-2 were 
used to test the antiviral activity of ivermectin. At 24 h, it 
has been shown around 93% decrease in viral RNA existing 
in the supernatant of samples treated with ivermectin in 
comparison with the vehicle DMSO. Likewise, nearly 99.8% 




Although, the use of NSAIDs was hypothesized to use 
against COVID-19 but its use has been a topic of debate 
and controversy. It is suggested that the use of NSAIDs 
can increase the risk of cardiovascular (CVS) and respira-
tory complications which are reported as the most lethal 
complications of COVID-19.[78] In addition, several studies 
demonstrated a pragmatic evidence linking NSAIDs with 
both respiratory and cardiovascular adverse effects in clini-
cal settings, but until now no evidence has been seen re-
lating specifically to people with COVID-19. Further studies 
are required to demonstrate some reasonable and caution-
ary strategies for the public to avoid the incidence of these 
probable adverse effects. Regular NSAIDs use should be 
avoided as a first line therapy for symptomatic treatment 
of COVID-19. However, NSAIDS may be recommended for 
some other symptoms of COVID-19 such as management 
of musculoskeletal pain and as aspirin may be used for the 
secondary prevention of CVS disease. The sole study that 
hypothesized NSAIDs effectiveness in COVID-19 patients, 
has evaluated indomethacin effects, demonstrating its in-
vitro potent anti-viral activity against canine coronavirus. 
This study reported indomethacin as potent inhibitor of 
viral replication and protects the host cell from viral dam-
age. This study was further explored in-vivo and in human 
SARS-CoV at a dose concentration of 1mg/kg.[79, 80]
Corticosteroids (Glucocorticoids)
Similarly some reports stated that the use of corticosteroids 
may exacerbate symptoms of coronavirus infection in pa-
tients. Meantime, there are some evidences recorded that 
corticosteroids may exert some beneficial effects in the 
early acute phase of infection. Various studies recommend-
ed the use of corticosteroids as preferred over NSAIDS for 
COVID-19 treatment.[80] Taken together, key findings are 
generally emphasizing the use of corticosteroids, especial-
ly in regard of the outbreak of the SARC-CoV, as they are 
well known as inflammatory modulators. Several studies in 
mice models and human samples[81] and mice[82] reported 
that corticosteroids such as glucocorticoids has seemed 
to be effective in diminishing immuno-pathological viral 
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damage response. Nevertheless, the WHO has not recom-
mended the routine administrations of systemic cortico-
steroids in patients with COVID-19.[83]
Recently, to investigate the efficacy of corticosteroid treat-
ment in COVID-19 patients, one observational study in 
the two COVID- 19- designated hospitals in Wuhu, Anhui 
province, China, was undertaken by Zha et al.[84] Thirty- one 
SARS- CoV- 2 infected patients were treated at the two 
designated hospitals. Eleven of 31 patients received cor-
ticosteroid treatment but they did not find an association 
between therapy and outcomes in patients without acute 
respiratory distress syndrome. The researchers stated that 
an existing HBV infection may delay SARS-CoV-2 clearance, 
and this association should be further evaluated.[84] Recom-
mendation from WHO against handling patients with CO-
VID‐19 demonstrated that corticosteroid treatment did not 
improve clinical outcomes for patients with SARS or MERS 
also even though medical societies in China recommend 
their sensible use.[85]
Recently a research study conducted in UK at the Queen’s 
Medical Research Institute Edinburgh in 2020 concluded 
that no distinctive reason occurs to assume that patients 
with nCoV-2 infection could get the advantage from cor-
ticosteroids, apart from this there might be a chance more 
likely to harm the patient with such treatment.[86] On April 
3, 2020, a study published in the Journal of Clinical Endocri-
nology & Metabolism is warning clinicians and patients that 
individuals taking glucocorticoids may be at an increased 
risk if they were to become infected during the pandemic. 
Furthermore, these endocrinologists have shown concern 
that patients may be unable to mount a normal stress re-
sponse with COVID-19.[87]
Combining Anti-viral and Anti-inflammatory 
Treatments
A research conducted by medical team at the Imperial Col-
lege London, UK described a collection of accepted drugs 
that could possibly prevent endocytosis mediated by clath-
rin and by this means prevents viral infection to the cells.[88] 
Baricitinib drug is recognized as inhibitor of Janus kinase 
(JAK) and it is advised that the drug can be of usage in com-
bating SARS-CoV-2 infections. Along with baricitinib, fedra-
tinib and ruxolitinib were also expected to be beneficial to 
counter the consequences of the high levels of cytokines 
characteristically detected in people with COVID-19. To 
confirm the hypothesis all the three drugs were subjected 
to proper clinical testing.[10]
After the uncertain outcome of clinical trials, it was conclud-
ed that these drugs have not that much potency to lower 
the rate of viral infection at tolerated doses though they 
might be capable to decline the inflammatory response of 
host by hindering JAK. Furthermore, it was expected that 
combinations of baricitinib with direct-acting antivirals i.e. 
((LPV/r, remdesivir) might diminish viral replication, viral 
infection, plus the unusual host inflammatory response as 
the drug possesses anti-inflammatory properties,[89] mini-




It is an immunosuppressant drug that approved to treat 
patient with rheumatoid arthritis[90] and systemic juvenile 
idiopathic arthritis[91] where it is available as an intravenous 
(IV) or subcutaneous (SC) formulation. It is a recombinant 
humanized monoclonal antibodies that acts by specifically 
binding to cell surface bound IL-6 receptor (mIL6R) and 
soluble IL-6 receptor (sIL6R) and inhibit signal transduction 
thus inhibit inflammatory response. Ina study by Xiaoling 
Xu et al. held in February 2020, 21 critical COVID-19 per-
sons (their average age was 56.8±16.5 years, ranged from 
25 to 88 years,) treated with tocilizumab were analyzed. 
The study stated that tocilizumab efficiently improves clini-
cal signs and suppress the worsening of severe COVID-19 
patients. There were no problems associated with tocili-
zumab administration and no history of illness worsening 
or death. Hence, tocilizumab is an effective drug in severe 
individuals with COVID-19, that provided a new therapeu-
tic protocol for this fatal COVID-19 infections.[6] A random-
ized, placebo-controlled, singled-blind, multicenter, phase 
II clinical trial study launched on March 20, 2020 holding 
in Italy with the title of Tocilizumab in COVID-19 Pneumo-
nia (TOCIVID-19). TOCIVID-19 patients in the experimental 
group received a dose of 8 mg/kg (up to a maximum of 
800mg per dose), with an interval of 12 hours by IV infu-
sion besides the routine treatment. Patients in the control 
group also administered routine treatment and the similar 
dose of a placebo. The trial is expected to conclude by the 
end of December 2020.[31] In addition, the health ministry 
of Turkey has offered option regarding the use of tocilizum-
ab in severe COVID-19 ICU patients with cytokine release 
syndrome.[46]
BCG Vaccine
The Bacillus Calmette-Guérin (BCG) vaccine is live attenu-
ated vaccines that was developed in the early part of the 
20th Century by Albert Calmette and Camille Guérin by sub-
culturing different strains of Mycobacterium tuberculosis 
and Mycobacterium bovis to protect against tuberculosis. 
Although, it is thought to reduce the risk of contracting 
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tuberculosis by approximately 50%, there are some proofs 
clarified that the BCG vaccine shows non-specific protec-
tion and decrease the morbidity and mortality rates of 
pathogen some of which causes acute respiratory tract in-
fection.[92, 93] In addition, the BCG vaccine can enhance the 
immune response to other vaccines as well. One study in-
cluding the administration of the BCG vaccine previous to 
the influenza vaccine exhibited that antibody titer to the 
latter was significantly improved[94] which stated that fol-
lowing the BCG inoculation, there was a fast seroconver-
sion and improved pro-inflammatory leukocyte response, 
and even a modification of cytokine responses against dis-
similar pathogens. 
The Semmelweis University published on its official web-
site that according to a recent epidemiological study there 
is a correlation between the use of the BCG and COVID-19 
infections and the course of the disease where mortality 
due to COVID-19 is reduced in countries where there are 
vaccination of newborns with BCG. On the other hand, in 
countries where BCG vaccination has been suspended (eg. 
Spain, France) or compulsory vaccination has never been 
introduced (eg. Italy), the mortality rate of the viral infection 
is high.[95] The exact molecular mechanism which activates 
the BCG vaccination against tuberculosis, COVID-19 and 
other upper respiratory tract infections is very little known. 
Data from some animal studies suggest that the pleiotropic 
protective effect of the BCG vaccine enhances the forma-
tion of inflammatory mediators, which boost non-specific 
antiviral immunity.[96] A recent study published by Gursel 
et al. hypothesized that BCG vaccination policies adopted 
by different countries might influence the SARS-CoV-2 
transmission patterns and/or COVID-19 associated morbid-
ity and mortality through the vaccine’s capacity to confer 
heterologous protection. In addition, it is postulated that 
until a specific vaccine is developed, SARS-CoV-2 vulnera-
ble populations could be immunized with BCG vaccines to 
attain heterologous nonspecific protection from the new 
coronavirus.[95, 96]
Monoclonal Antibody Therapy
Monoclonal antibodies (MAs) are a new tool of immunother-
apy in infectious disease prevention and it is considered a 
multipurpose class of pharmaceuticals which have been ef-
fectively used by pharmaceutical manufacturing to deliver 
a competent therapeutic intervention with a highly specific 
therapy against specific disease.[97] Rapid public health inter-
ventions by using MAs are highly essential to stop disease 
spread and consider as a way to limit COVID-19 pandemic as 
well as to reduce the likely future outbreaks through its abili-
ty to deactivate the virus and stop further infection. Similarly, 
the early administration or hyper-immune immunoglobulin 
can possibly decrease the viral infection and disease mortal-
ity. The passive MAs act through its ability to identify epitope 
regions in the foreign virus particle which can reduce the 
virus replication and disease severity. This passive MA can 
obtain from the serum of the infected patients or it can be 
made in the lab.[97-99]
The pathogenic mechanism of COVID-19 start by virus at-
tachment and entry to the host cells through linking of re-
ceptor binding domain (RBD) located in the spike protein (S-
protein) present on COVID-19 virus membrane and target 
host cell surface receptors such as Angiotensin converting 
enzyme 2 (ACE 2) which is the same receptor that utilized 
by SARS-CoV to enter and attach to the host cell.[100] As both 
SARS-CoV and COVID-19 viruses use same host cell surface 
receptor, probable blocking strategies tested to stop virus 
access to host cell could be used against COVID-19. There 
are many reported MAs directing the RBD region of S-pro-
tein of SARS-CoV and MERS-CoV which showed promising 
results in vitro and in vivo that could be theoretically ef-
fective against COVID-19 as 80R, CR3014, CR3022, F26G18, 
F26G19, m396, 1A9, 201, 68, 4D4, S230, MERS-4, MERS-27, 
4C2, m336, G4, D12, JC57-14, MERS-GD27, MERS-GD33, 
LCA60, MCA1, CDC2-C2, 7D10 and G2.[97] In addition, to get 
more effective disease prevention it was recommended to 
use the mixture of different monoclonal immunoglobulins 
which identifies different epitopes on the viral surface. So, 
the Monoclonal antibody cocktail may show extra effective 
anti-virus activity that can rise the efficiency of the treat-
ment and inhibit the viral escape.[101] 
Unfortunately, the use of MAs as therapeutic tool for CO-
VID-19 have some disadvantages during its biosynthesis 
where the devices that use for manufacturing of MAs are 
labor exhaustive, expensive and time consuming which 
outweighs the MAs clinical application especially against 
emerging pathogen. Although, there is a more growth to-
wards the progress of MAs therapy for CoV infection, no 
MAs have yet been successfully used.
Plasma Therapy
Plasma therapy or intravenous immunoglobulin (Ig) treat-
ment which is considered as a kind of passive immuno-
globulin-G (IgG) antibodies and it is specific against CO-
VID-19 by stimulating the immune response in newly 
infected individuals.[102] The presence of this Ig in the se-
rum of infected individuals will help in COVID-19 infec-
tion prophylaxis and treatment and it is more effectual 
when introduce directly after the onset of symptoms. The 
passive antibodies from human convalescent serum neu-
tralizes COVID-19 microorganisms or their toxins through 
stimulation of antibody-dependent cellular cytotoxicity or 
phagocytosis.[103] IgG antibodies strengthen our immune 
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response by two mechanisms; firstly by its fragment anti-
gen-binding [F(ab')2] portion, that recognizes the antigen 
and secondly by crystallizable fragment (Fc), that consid-
ers significant for stimulation of the immune response by 
interacting with Fc receptors on B-cells and other innate 
immune cells. Additionally, the Fc portion also plays a sig-
nificant role in the activation of complement system and 
in the killing of microorganisms.[104] Plasma therapy has 
been used to treat individuals with chronic inflammatory 
and autoimmune diseases such as chronic lymphocytic 
leukemia, dermatomyositis, kawasaki disease, multiple 
sclerosis, lupus, and idiopathic thrombocytopenic purpu-
ra.[105-107] Moreover, it has been used as an anti-microbial 
agent against viruses, bacteria, and fungi in human and 
experimental models.[108, 109] 
The plasma therapy against CoV started during SARS out-
break in HONG KONG where 80 patients were treated with 
convalescent plasma in 2005 and the study reported that 
therapy had improved prognosis for all patients within 6 
days of plasma administration.[110] Another study in Taiwan 
published that three patients with SARS were cured with 
500 mL therapeutic plasma, resulting in a reducing serum 
virus titer in all three patients.[98] Ko JH et al. in 2018, showed 
that three patients with MERS in South Korea were treated 
with therapeutic plasma, but only two of them had passive 
antibody in their plasma.[111] During the current pandemic 
there is a study that therapeutic plasma was utilized for 
treatment of patients with COVID-19 in China, however, a 
little information are existing from the epidemic in China 
and published reports which involved small numbers of 
patients, the available data recommends that therapeutic 
plasma administration decrease viral load and was safe.
[112] A recent report of 10 patients with severe COVID-19 
were treated with therapeutic plasma and all 10 patients 
had enhancement in symptoms disappearance (e.g. fever, 
cough, shortness of breath and chest pain) within 1-3 days 
of administration. They also demonstrated radiological im-
provement in pulmonary lesions. 
Recently drug regulatory authority of Pakistan (DRAP) per-
mits clinical trials of plasma therapy for treatment of CO-
VID-19[113] and there are five clinical trials USA have been 
projected to estimate human anti-SARS-CoV-2 plasma for 
the prevention and handling of COVID-19.[114] In addition, 
Turkey have started convalescent plasma from recovered 
patients to use for patients who had severe disease.[46] All of 
the previous and current conclusions suggest that admin-
istration of therapeutic plasma is harmless, diminishes viral 
infection and may improve clinical consequences. More-
over, COVID-19 therapeutic sera could be helpful to treat 
patients with initial symptoms. 
Interferon (IFN) Alpha 2b
This drug reflects the recombinant form of the protein in-
terferon alpha-2 which was made by recombinant process 
in Escherichia coli to combat viral infections triggered by 
the HIV, hepatitis B and C, plus respiratory Papillomatosis. 
Recently, this medication was used in clinical trials to treat 
patients with SARS-CoV-2, although there are no published 
results of those trials in the peer-reviewed scientific litera-
ture yet. During this COVID-19 outbreak, China has chosen 
Cuban drug IFN alpha-2b along with 30 others to treat CoV 
patients.[115] Luis Herrera Martínez, a scientific and commer-
cial advisor to the President of Bio-Cuba-Farma, stated that 
the drug “the antiviral interferon alpha 2b has the advan-
tage that in situations like these it has a mechanism to pro-
tect itself and its use prevents patients from reaching seri-
ous and complicated stage”.[116] IFN is known to have cured 
more than 1,500 patients with CoV and is among the drugs 
of choice for the WHO.[117] The specific method for adminis-
tration of IFN-α is vapor inhalation at a dose of 5 million U 
(and 2 mL of sterile water for injection) for adults, 2 times/
day.[24, 54]
Anti-cytokines
A retrospective observational study conducted in china 
with the aim to determine alterations of markers of severe 
COVID-19 patients in peripheral blood, which might be 
worthy in surveillance of the disease. It was concluded that 
the baseline level of IL-6 is of close relationship with the se-
riousness of COVID-19, and the elevated IL-6 was consider-
ably related to the clinical signs of critical patients. Decline 
of IL-6 was considered to be closely associated to treat-
ment effectiveness. Researchers decided after collective 
outcome of the study, that the dynamic changes in level 
of IL-6 could be utilized as a marker for disease monitoring 
in severe COVID-19 patients.[117] The University of Manches-
ter and Salford Royal Hospital in the UK documented surge 
of pro-inflammatory cytokines in the blood, together with 
TNF, interferon γ, interleukin (IL)-1, IL-6 in ICU patients with 
COVID-19.[118]
A report covering a trial of 21critical COVID-19 patients in 
China and one case study belonging to France got medi-
cal advantage with the anti-IL-6 receptor antibody. Out of 
many, only few drugs such as adalimumab or infliximab 
and anti-TNF antibodies have high potency, efficacy, avail-
ability, and a well-established safety profile.[119] Recently, a 
study published by Bingwen liu and his colleagues in El-
sevier Journal of autoimmunity proposed a new promis-
ing approach to utilize IL-6 blocking agents could manage 
nCoV-2-induced (CRS) Cytokine release syndrome which 
is a deadly multiple organ dysfunction in the body of CO-
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VID-19 patients and symbolizes a potential therapeutic 
target.[85] This approach still needs further investigatory re-
search to determine the actual outcome.
Anticoagulant Treatment
The use of anticoagulant for severe COVID-19 treatment 
has been recommended by some general proficient agree-
ment 120 due to the risk of disseminated intravascular 
coagulation (DIC) and venous thromboembolism (VTE). 
In addition, a previous study identified a first stage of 
sepsis-associated DIC called “sepsis-induced coagulopa-
thy (SIC)"[121] as well long-term bed-staying and probabil-
ity of getting hormone therapy increases the risk of VTE 
in severe COVID-19 cases.[122] There was a study published 
by Iba et al. has been confirmed that the patient with SIC 
benefit from anticoagulant therapy.[123] The mechanisms by 
which COVID-19 can cause coagulopathy complication are 
by inducing the impairment of endothelial cells function 
which results in excess thrombin formation and fibrinolysis 
cessation that specified by a hypercoagulable state in pa-
tient with infection such as COVID-19.[124] Furthermore, the 
hypoxia which reported in severe COVID-19 cases can trig-
ger thrombosis not only through raising blood viscosity, 
but also through a hypoxia-induced transcription factor-
dependent signaling pathway.[125]
A recent lung organ dissection has been found an evidence 
for presence of obstruction and microthrombosis forma-
tion in lung small vessels of serious patient with COVID-19.
[126] Low molecular weight heparin (LMWH) was the best 
and most used as prophylactic dose due to its anti-inflam-
matory effect, its ability to prevent DIC and SIC.[127] A recent 
retrospective study in Tongji hospital, Wuhan, Hubei, China 
reported that anticoagulant treatment chiefly with LMWH 
seems to cause a better prognosis in severe COVID-19 pa-
tients meeting SIC criteria or with noticeably raised D-di-
mer level.[120] It has been observed that COVID-19 patients 
with coagulation disorder have higher chances of mortal-
ity. For this reason anticoagulant drugs had been added to 
their treatment algorithm.[46] It is suggested that only the 
patients with severe COVID19 infection whom need for 
intensive care treatment and meeting SIC criteria or with 
severe elevated D-dimer may benefit from anticoagulant 
therapy. 
Antihypertensive Drugs
Angiotensin-converting enzyme inhibitors (ACE-Is) and 
angiotensin receptor blockers (AR-Bs) are generally pre-
scribed for patients with high blood pressure (B.P). ACE 
hydrolyzes angiotensin-I hormone into the vasoconstrict-
ing angiotensin-II resulting in high B.P. ACE2 act to neutral-
ize the activity of ACE and lowering B.P by decreasing the 
amount of angiotensin-II. As ACE2 serves as the co-receptor 
for SARS-CoV-2, this has created some to hypothesize that 
reducing the levels of ACE2, in cells, might assess in com-
bating the infection. On the other hand, ACE2 has been 
revealed to have a shielding effect against virus-induced 
lung injury by growing the generation of the vasodilator 
angiotensin (1–7).[128] Both ACE-Is and AR-Bs have been 
determined in rodent studies to induce ACE2 expression 
therefore may worsen the severity of CoV infections.[129] 
However, numerous professional societies and regulatory 
organizations have suggested continuing standard ACE-
Is and AR-Bs therapy. Regardless of the absence of proof, 
there have been thoughts for both the continuation and 
termination of ACE-Is, AR-Bs, or both throughout the treat-
ment for COVID-19 in patients with hypertension.[130]
Traditional Chinese Medicines (CM)
A study reported the historic records for infection preven-
tion in CM along with former clinical evidence on CM pre-
vention for similar public health emergencies such as SARS 
and H1N1 (Hemagglutinin Type 1 and Neuraminidase Type 
1) influenza. Available literature presented that the practice 
of CM to prevent epidemics of contagious diseases can be 
traced back to ancient CM practice over centuries, and its 
effective results were preliminarily demonstrated by mod-
ern human clinical researches when applied to SARS and 
H1N1 influenza epidemics signifying that historical CM ex-
perience is a valuable approach.[131] 
Based on the complete investigations of the prevention 
programs allotted by 23 provinces since the COVID-19 out-
break, it is established that the main CM principles in pre-
venting COVID-19 were to tonify qi to defend from external 
pathogens, discharge heat and disperse wind, and resolve 
dampness with aroma. It was also related to the features of 
CHM formulae for preventing "outbreak" in previous times 
and SARS in 2003.[132] The six most frequently used herbs 
were Radix (Fangfeng), Glycyrrhizae Radix Et Rhizoma (Gan-
cao), Saposhnikoviae Astragali Radix (Huangqi), Lonicerae 
Japonicae Flos (Jinyinhua), Atractylodis Macrocephalae 
Rhizoma (Baizhu), and Forsythiae Fructus (Lianqiao). As-
tragali Radix (Huangqi), Saposhnikoviae Radix (Fangfeng), 
and Atractylodis Macrocephalae Rhizoma (Baizhu) are all 
ingredients of a classical herbal formula Yupingfeng Pow-
der, for tonifying qi to keep from external pathogens. 
In Lao, et al's controlled study[132] of CM formula for pre-
venting SARS, Yupingfeng Powder was also the main com-
ponents. Many findings have confirmed that Yupingfeng 
Powder has antiviral, anti-inflammatory and immunoregu-
latory effects.[133] Japonicae Flos (Jinyinhua) and Forsythiae 
Fructus (Lianqiao) are the main parts of Yinqiao Powder, 
which is a classical formula used to prevent and treat re-
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spiratory infectious diseases in ancient.[134] An experimen-
tal investigation found that the consequence of Yinqiao 
Powder (银翘散) in preventing and treating upper respira-
tory tract infection could be described by its antibacterial 
and antiviral properties and improvement of the function 
of upper respiratory mucosal immune system.[135] A large-
scale, multicenter, randomized trial found that Yinqiao 
Powder along with heat-clearing formula could decrease 
time to fever perseverance in patients with the H1N1 influ-
enza virus infection.[134]
These days, the National Health Commission of China has 
not issued a CM prevention program for COVID-19. There 
may be multiple reasons like, first, according to the CM the-
ory of three-factors concerned treatment (Sanyin Zhiyi, 三
因制宜), due to the differences of regional, individual, and 
seasonal factors in the distribution and occurrence of dis-
eases, these aspects should be measured in prevention and 
treatment,[136] and second, nonexistence of solid proof of 
CM formula for COVID-19. However, a single case study by 
Ren et al. stated that Qingfei paidu decoction is controlling 
the symptoms of COVID-19.[137] In addition, H.L. Zhang and 
Y.X.Zhu stated in another single patient case report that 
the highly suspected case of novel coronavirus pneumo-
nia were recovered with the use of CM.[138] We recommend 
that the protection should also be given attention to when 
taking CHM formula to prevent COVID-19, especially when 
they are used for long time. The people should select the 
prescriptions under the guidance of CM doctors according 
to the program issued by provincial health authorities, and 
avoid taking the prescriptions or herbs with unknown ori-
gin and without officially approval. 
Others
Temperature and Humidity
In order to prevent COVID-19, multiple environmental fac-
tors are playing important role to cope this disease. Tem-
perature and humidity are also important in this regard. 
A research validated an inverse relation between COVID 
-19 mortality and temperature, while a direct relation with 
diurnal temperature range (DTR). Multiple research have 
demonstrated that respiratory diseases mortality elevated 
with falling temperature,[139] and was strongly linked with 
decreased temperature.[140] While another research estab-
lished that both heat and cold effects might have hostile 
impacts on respiratory mortality.[141] The increased DTR 
have shown increased risk of mortality for respiratory and 
cardiovascular diseases by a study conducted in 30 East 
Asian cities.[142] During cold conditions, the accumulative 
risk of respiratory, cardiovascular and non-accidental death 
increased at high DTR values in Tabriz.[143] A time depen-
dent research conducted in Shanghai for the effect of DTR 
on daily chronic obstructive pulmonary disease (COPD) 
death rate showed that for each 1°C increase in the 4-day 
moving average for DTR counted for 1.25% of amplified risk 
of COPD mortality. 
In a demographic research, the outbreak of SARS in Guang-
dong in 2003 slowly washed-out with the warming weath-
er approaching, and was completely ended until July.[144] It 
has been recorded that the temperature and its deviations 
might have affected the SARS plague. A research in south 
Korea have found that the menace of influenza incidence 
was considerably elevated with decreased daily tempera-
ture and relative low humidity, and a direct significant re-
lationship was perceived for DTR.[145] Further, temperature 
and DTR have been associated to the death from respira-
tory diseases. A study confirmed that absolute humidity 
had significant correlations with influenza viral transmis-
sion and survival rates.[146] 
Few studies determined that the COVID-19 was associated 
to the climatological factors, which reduced with the tem-
perature growing,[147] but their effects on the death rate has 
not been described. Scientists established that respiratory 
infection was increased during unusually cold and low hu-
midity circumstances,[148] representing decreased humidity 
might too be a significant risk factor for respiratory dis-
eases. A 25 year research study established that humidity 
was a significant element of mortality, and low -humidity 
levels might cause a huge increase in mortality rates, pos-
sibly by influenza -related mechanisms, similar to a study 
carried out in the United States.[149] Epithelial damage and/
or reduction of mucociliary clearance can be caused by 
breathing dry air, and then lead to expose the host more 
vulnerable to respiratory virus infection; The creation of 
droplet nuclei is vital for transmission, but exhaled respira-
tory droplets settle very quickly at high humidity so that it 
is hard to contribute to influenza virus spread.[150] 
Future Perspective: The Development of 
Prophylactic COVID-19 Vaccines
The increased pace of SAR-CoV-2 contagions and affected 
nations, the whole struggle is on making an effective SARC-
oV-2 vaccine in various countries. Following the standard 
operating procedures (SOPs) and knowledge from SARS 
and MERS vaccines development, many research scientist 
have started working on SAR-CoV-2 vaccine development 
within only a few weeks after the outbreak. Almost 37 bio-
pharmaceutical companies and academic sectors after two 
months of this outbreak started competition for the devel-
opment of prophylactic vaccine by utilizing several tech-
niques including DNA, mRNA, recombinant protein and ad-
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enoviral vector.[18] Maximum vital information are needed 
to be gather for the formation and validation of vaccines, 
which includes investigating final target antigen(s), corre-
lated-immune protection, animal models, immunization 
route, production facility, scalability, outbreak forecasting, 
target product profile (TPP), and target population. Factors 
like International cooperation as well as technology alloca-
tion between experts are too needed and helpful for SARS-
CoV-2 vaccine development. Knowledge learnt from Zika 
was used to speed up the available vaccine during current 
plague, along with clinical trails the preclinical studies of 
SAR-CoV-2 vaccine nominees may need to be performed. 
Although prior of entering into clinical testing, the produc-
tion process must be asses by some regulatory agencies for 
preclinical information to make sure volunteers’ safety.[151] 
Vaccine formation is an expensive and lengthy process. 
Attention is high, and it normally requires numerous can-
didates and many years to develop a licensed vaccine.[152] 
Due to high price and maximum failure rates, researchers 
usually follow a linear sequence of phases, with manifold 
breaks for manufacturing-process checks or data analysis. 
A new pandemic paradigm is required for the developing 
a vaccine, with a quick start and numerous steps imple-
mented in comparable prior to confirming a successful re-
sult of another step, hence, resulting in higher economical 
risk. For instant, for platforms with experience in humans, 
phase 1 clinical trials may be able to progress in compa-
rable with testing in animal models. Table 2 contains some 
of the potential vaccines under clinical trials by different 
pharmaceutical companies and universities to cope the 
COVID-19 plague.[153]
Discussion
This review article is compiled based on the currently pub-
lished data for the treatment of COVID-19. At present time, 
there is no an effective vaccine or specific antiviral drugs for 
coping COVID-19. Thus, alternatively we have to depend on 
imposing firm precautionary and control trials that dimin-
ish the menace of possible disease spread.[6] This article un-
doubtedly validates that the existing data are not enough 
to suggest any treatment for abolition of COVID-19 to be 
used at the clinical level. As the human research are lack-
ing comparative data thus it is very difficult to say whether 
the patient get treated are because of the use of a specific 
medicine or the general clinical care gained. Most of the 
in vitro research, are the indicative of potential valuable 
effects although the data are too maiden to be utilized as 
rationale for clinical consumption.[6, 24]
Scientists are finding effective and appropriate vaccine 
nominees and therapeutics for monitoring the deadly 
COVID-19. From the recently conducted in vitro study, 
the results on some human trails against COVID-19 are 
encouraging since some antiviral, antimalarial and other 
pharmacological and no-pharmacological treatments were 
Table 2. The Development of Prophylactic COVID-19 Vaccines
Platform    Type of Candidate Developer CoV Target Current stage of Clinical Same platform for
  vaccine   Evaluation or regulatory non-CoV candidates
     status of CoV candidate 
NonReplicating Adenovirus Type CanSino Biological COVID-19 Phase2 ChiCTR2000031781 Ebola
Viral Vector 5 Vector Inc./Beijing Institut   Phase1 ChiCTR2000030906
    of Biotechnology 
Inactivated  TBD Osaka University/  COVID-19 Pre-Clinical
   BIKEN/NIBIOHN
Live Attenuated  Deoptimized live Codagenix/Serum COVID-19 Pre-Clinical HAV, InfA, ZIKV, FMD,
Virus attenuated vaccines Institute of India   SIV, RSV, DENV
NonReplicating  ChAdOx1 University of Oxford COVID-19 Phase 1/2 (not yet MERS, influenza, TB, 
Viral Vector    recruiting) NCT04324606 Chikungunya, Zika,
      MenB, plague
NonReplicating  Ad26 (alone or with Janssen Pharmaceutical COVID-19 Pre-Clinical Ebola, HIV, RSV
Viral Vector MVA boost) Companies 
NonReplicating  MVA expressing Centro Nacional COVID-19 Pre-Clinical HIV, HCV, chikungunya,
Viral Vector structural proteins Biotecnología (CNB-CSIC),    Ebola, zika, malaria,
   Spain   leishmania
Protein Subunit  microneedle arrays Univ. of Pittsburgh COVID-19 Pre-Clinical MERS
  S1 subunit
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shown to be highly effective in preventing the infection.[154] 
Though, the fact that needs careful consideration is the 
safety profile of all these treatment tactics and required 
to be verified through properly conducted clinical trials. 
Therefore, the concentration of the studies may important 
to be on the direct human clinical approaches in maximum 
quantity along with in vitro studies to approve the efficacy 
as well as protection of all pharmacological treatments.
Conclusion
As the Pandemic situation is spreading in the whole world, 
scientists around the globe are dynamically discovering 
medications that would be effective in fighting against 
COVID-19. At the present, there are not any certified anti-
virals drugs specific for COVID-19. However, the safety and 
efficiency of these already available potential drugs in the 
treatment of COVID-19 are required be confirmed in fur-
ther preclinical and clinical trials. Furthermore, this viral 
pandemic needs to be defied with a joined national ap-
proach that can be executed rapidly on a very large scale. 
The capability to mobilize and to stay nimble in adjusting 
to these challenges is paramount. Municipal buy-in is vital 
for all residents to abide by the rules and recommenda-
tions. Cooperation and sharing knowledge of COVID-19 
among countries are imperative to establish more effective 
policies to control the spread of future pandemic and cur-
tail morbidity and mortality. 
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